General characterization of T2DM patients and healthy controls. by Ningning Wang (560944)

Subjects:

Antihypertensive treatment of 151 T2DM patients with hypertension at different subgroups. by Ningning Wang (560944)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different normotension subgroups. by Ningning Wang (560944)

Subjects:

Characteristics of the study group. by P.G.J. ter Horst (21743830)

Subjects:

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning medicament(s) use and Low Semen Quality (LSQ). by P.G.J. ter Horst (21743830)

Subjects:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes in hypertensive (A) and normotensive (B) patients. by Ningning Wang (560944)

Subjects:

A. Proportion of men with Low Semen Quality (LSQ) including 95% confidence interval (CI) versus prevalence, overall and for men on medication(s) (M); B: Point estimates with 95% CI... by P.G.J. ter Horst (21743830)

Subjects:

Prevalence of low semen quality including 95% confidence interval (CI) for medication at the ATC 5 level. by P.G.J. ter Horst (21743830)

Subjects:

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning a selection of medicaments with n ≥ 10 medicament users and p < 0.1 by univariate analysis.... by P.G.J. ter Horst (21743830)

Subjects:

Top 10 significant functional annotations of down-regulated DEGs. by Meitner Cadena (22216261)

“…Functional annotations are ordered by decreasing significance, with color indicating significance level based on the legend’s color scale, the ratio of genes on the horizontal axis, and DEG count represented by circle size.…”

Distribution of SNPs and their frequencies based on mutation classes. by Sadia Afrin Runa (22504971)

Subjects:

Changes in the white blood cell count. by Lu Yang (30847)

“…The leukocyte and neutrophil counts of the patients in the bone pain group were significantly higher than those of the patients in the no bone pain group, P(WBC) = 0.001, P(ANC) = 0.002.…”

Analysis of randomized controlled trials stratified based on treatment duration. by Solima Sabeel (9545738)

Subjects:

Detailed table of sandstones mechanical parameters change. by Wenyu Lv (20139458)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

(A) Side image of epoxy resin-made abutment-analog base and prosthesis; (B) Front image of epoxy resin-made abutment-analog base and prosthesis. by Long Li (6555)

Subjects:

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

Log2 fold change (FC), mean and standard deviation (SD) of each lipid specie from the normal liver (NL) and simple steatosis (SS) groups, and adjusted p-values. by Laia Bertran (3685147)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”